Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects
Language English Country Switzerland Media print
Document type Journal Article
PubMed
1414682
DOI
10.1007/bf01991241
Knihovny.cz E-resources
- MeSH
- Acetylmuramyl-Alanyl-Isoglutamine * analogs & derivatives chemistry pharmacology MeSH
- Adjuvants, Immunologic pharmacology MeSH
- Edema chemically induced pathology MeSH
- Rats, Inbred Strains MeSH
- Indomethacin pharmacology MeSH
- Rabbits MeSH
- Rats MeSH
- Macrophages drug effects MeSH
- Foot pathology MeSH
- Structure-Activity Relationship MeSH
- Inflammation chemically induced pathology MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Acetylmuramyl-Alanyl-Isoglutamine * MeSH
- Adjuvants, Immunologic MeSH
- Indomethacin MeSH
Immunomodulatory agents, muramyl dipeptide (MDP) and several of its analogues, i.e. adamantylamide dipeptide, murametide, murabutide and their glucosaminylated derivatives, were tested for edemagenic activity in rats. Given systemically in aqueous solutions, only MDP and glucosaminylated MDP, at the dose of 3 mg/kg (s.c. or p.o.), were found to produce edematous swelling of the paws. Local (intra-pad) application of MDP was more effective than the systemic one. Supernatants of macrophages, in vitro cultured in presence of MDP, caused the swelling as well. The edema was of a transient nature. After reaching the maximum severity (about 6 h after injection of MDP solution or 1 h after macrophage supernatants), it was subsiding and disappeared completely within approximately 6 days after cessation of the treatment. It was found that this type of rat paw edema is probably a prostaglandin-dependent consequence of macrophage activation. Hypotheses on the involvement of immunoregulatory cytokines, and possible chemical structure-inflammatory activity relationships have been suggested.
See more in PubMed
Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):419-26 PubMed
J Infect Dis. 1980 Nov;142(5):708-15 PubMed
Int J Immunopharmacol. 1979;1(1):35-41 PubMed
Am J Physiol. 1984 Sep;247(3 Pt 1):C169-74 PubMed
Infect Immun. 1982 Feb;35(2):417-24 PubMed
J Immunol. 1988 May 1;140(9):3021-5 PubMed
Proc Natl Acad Sci U S A. 1987 Jun;84(12):4273-7 PubMed
Clin Immunol Immunopathol. 1989 Dec;53(3):488-98 PubMed
J Exp Med. 1981 Apr 1;153(4):1021-6 PubMed
Eur J Immunol. 1984 Oct;14(10):898-901 PubMed
Int J Immunopharmacol. 1982;4(5):451-62 PubMed
Ryumachi. 1981;21 Suppl:149-56 PubMed
Infect Immun. 1981 Feb;31(2):758-66 PubMed
J Clin Invest. 1988 May;81(5):1384-9 PubMed
J Clin Invest. 1986 Mar;77(3):1020-7 PubMed
J Exp Med. 1986 Jun 1;163(6):1433-50 PubMed
Eur J Immunol. 1988 Jun;18(6):957-9 PubMed
Infect Immun. 1986 Sep;53(3):511-6 PubMed
Agents Actions. 1989 Jan;26(1-2):186-8 PubMed
Infect Immun. 1980 Jul;29(1):70-5 PubMed
FASEB J. 1989 Dec;3(14):2565-73 PubMed
Infect Immun. 1982 Feb;35(2):674-9 PubMed
Annu Rev Immunol. 1984;2:335-57 PubMed
J Immunol. 1990 Mar 15;144(6):2223-32 PubMed
Science. 1989 Feb 24;243(4894 Pt 1):1066-8 PubMed
N Engl J Med. 1983 Mar 10;308(10):553-8 PubMed
Infect Immun. 1980 May;28(2):624-6 PubMed
Infect Immun. 1986 Sep;53(3):517-21 PubMed
Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472-5 PubMed
Microbiol Immunol. 1986;30(7):717-23 PubMed
Methods Find Exp Clin Pharmacol. 1984 Nov;6(11):667-9 PubMed
Science. 1986 Oct 24;234(4775):470-4 PubMed
